Digital Drug Prediction

The 4th of our 5 research studies funded by the A-T Global Alliance is commencing on the 1st of December 2022.

The 36-month $270,000 study led by Dr Sam Nayler of QIMR in Brisbane is entitled Digital drug prediction informed by genetic analysis of stem cell-derived mini-brains from A-T patients.

The study aims to uncover how specific cell types are affected in A-T and build a model that has discovery and pre-clinical testing capability. Read more

Trial REadiness in A-T
(TREAT-AT)

As part of our A-T Global Alliance Grant Round, we are very excited to announce our 3rd of 5 new A-T research studies.

Dr Rita Horvath and Dr Anke Hensiek will study the clinical symptoms, blood biomarkers and brain imaging findings in a subgroup of A-T caused by the so called “UK mutation”.

The 36-month study commences on 1 Jan 2023 at a cost of $450,000. Read more

Our last Brisbane event was back in 2016 so we're long overdue for another opportunity to catch-up with old friends and raise much-needed funds for a great cause!

A-T Superstar, Luke Ogden, is hosting the 2nd Annual A-T Wheelathon on Saturday 4th March 2023 in Melbourne.

Check out the photos from last year

Study of Natural Killer Cells in A-T

We are delighted to be supporting yet another new A-T research study at Tor Vergata University of Rome in Italy as part of our A-T Global Alliance Grant Round.

The 24-month, AU$170,000 project will be led by Dr Margherita Doria (right) and Dr. Maria Giovanna Desimio. Read more

New Brain Research Study

We are delighted to be supporting a new A-T research study at the University of Nottingham as part of our A-T Global Alliance with Action for A-T (UK), The A-T Society (UK) and AEFAT (Spain).

The 24-month project entitled Brain-penetrating ATM gene therapy led by Dr James Dixon, will endeavour to combine gene therapy and editing to engineer an effective therapy to treat A-T in the brain. Read more